Back to Results

Genomma Lab Internacional SAB de CV (GNMLF)

Genomma Lab Internacional, S.A.B. de C.V. is a Mexico-based healthcare company incorporated in 1996 and listed on OTC Markets as common stock. Through itself and its subsidiaries, the company develops, sells, and markets branded pharmaceutical and personal care products in Mexico and international markets. Its portfolio spans a broad range of consumer health categories, including anti-acne and antibacterial products, shampoos and scalp-care items, skin treatments, pain-relief ointments, anti-fungal and digestive relief products, anti-wrinkle and antacid treatments, and other medicines and care products. The company is headquartered in Mexico City, Mexico.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-GNML.F
$1.04
35.3% Upside
Undervalued
Not available
Not available
Good
0.0%
October 28, 2026
7.5x
1.0x
0.7x
700.9 M
1 B
39.0%
69.0%
9.2
59.9%
77.3%
Valuation • Fair Value

Genomma Lab Internacional SAB de CV (OTC-GNML.F) Fair Value by Valuation Model

Review the available estimates for Genomma Lab Internacional SAB de CV (OTC-GNML.F), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.04

Estimated upside of 35.3% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.33

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0.97

Classic Ben Graham valuation formula reference.

Comps Fair Value

$0.90

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for Genomma Lab Internacional SAB de CV (OTC-GNML.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Genomma Lab Internacional SAB de CV (OTC-GNML.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

974.7 M

Current operating scale indicator.

Revenue Forecast

1.018 B

Forward revenue estimate.

EBITDA

222.8 M

Current operating profitability reference.

EBITDA Forecast

226.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Genomma Lab Internacional SAB de CV (OTC-GNML.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Genomma Lab Internacional SAB de CV (OTC-GNML.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.54

No elevated caution signal from this screen.

Altman Z-Score

9.2

Relatively strong balance-sheet zone.

FCF / Net Income

77.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Genomma Lab Internacional SAB de CV (OTC-GNML.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Genomma Lab Internacional SAB de CV (OTC-GNML.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 28, 2026

Days to Earnings

40

Dividend Yield

0.0%

No current dividend yield is indicated.

Payout Ratio

59.9%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Genomma Lab Internacional SAB de CV (OTC-GNML.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Genomma Lab Internacional SAB de CV (OTC-GNML.F) Stock FAQ

Data-supported answers about Genomma Lab Internacional SAB de CV (OTC-GNML.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.04
Estimated upside 35.3%
Valuation Rating
Undervalued
Estimated upside of 35.3%
Financial Health
Good
Current financial-health read

The current fair value estimate for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is $1.04. This implies an estimated upside of 35.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 35.3% versus the current market price.

The current financial health read for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is October 28, 2026.

The latest available data indicates no current dividend yield for Genomma Lab Internacional SAB de CV (OTC-GNML.F).

The current P/E ratio listed for Genomma Lab Internacional SAB de CV (OTC-GNML.F) is 7.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Genomma Lab Internacional SAB de CV is 700.9 M.

The current enterprise value listed for Genomma Lab Internacional SAB de CV is 1 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Genomma Lab Internacional SAB de CV is OTC-GNML.F, and the stock is listed on OTC Markets.

Genomma Lab Internacional SAB de CV (OTC-GNML.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Genomma Lab Internacional SAB de CV is 39.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Genomma Lab Internacional SAB de CV is 69.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B